Plasma Clusterin (ApoJ) levels are associated with adiposity and systemic inflammation

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Won, Jong Chul ^a   Park, Cheol Young ^b   Oh, Sang Woo ^c   Lee, Eon Sook ^a   Youn, Byung Soo ^d   Kim, Min Seon ^e  

^a Inje University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Dongguk University Ilsan Hospital   (South Korea)

^d Wonkwang University   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CHAPERONE; CLUSTERIN; FERRITIN; RETINOL BINDING PROTEIN 4; URIC ACID;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY MASS; CONTROLLED STUDY; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PROTEIN BLOOD LEVEL; URIC ACID BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; MIDDLE AGED; RISK FACTOR; SEX DIFFERENCE; YOUNG ADULT;

ADIPOSITY; ADULT; AGED; BODY MASS INDEX; CLUSTERIN; FASTING; FEMALE; HUMANS; INFLAMMATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SEX FACTORS; YOUNG ADULT;

EID: 84904962138     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103351     Document Type: Article

References (38)

1. Shapiro H, Lutaty A, Ariel A (2011) Macrophages, meta-inflammation, and immuno-metabolism. ScientificWorldJournal 11: 2509-2529.
2. Ronti T, Lupattelli G, Mannarino E (2006) The endocrine function of adipose tissue: an update. Clin Endocrinol (Oxf) 64: 355-365.
3. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121: 2111-2117.
4. Rajala MW, Scherer PE (2003) Minireview: the adipocyte - at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144: 3765-3773. (Pubitemid 37088727)
5. Choi-Miura NH, Takahashi Y, Nakano Y, Tobe T, Tomita M (1992) Identification of the disulfide bonds in human plasma protein SP-40,40 (apolipoprotein-J). J Biochem 112: 557-561.
6. Rosenberg ME, Silkensen J (1995) Clusterin: physiologic and pathophysiologic considerations. Int J Biochem Cell Biol 27: 633-645.
7. Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G, et al. (1991) Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. J Biol Chem 266: 11030-11036. (Pubitemid 21906907)
8. Trougakos IP, Gonos ES (2006) Regulation of clusterin/apolipoprotein J, a functional homologue to the small heat shock proteins, by oxidative stress in ageing and age-related diseases. Free Radic Res 40: 1324-1334. (Pubitemid 44698281)
9. Falgarone G, Chiocchia G (2009) Chapter 8: Clusterin: A multifacet protein at the crossroad of inflammation and autoimmunity. Adv Cancer Res 104: 139-170.
10. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093.
11. Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099.
12. Yu JT, Ma XY, Wang YL, Sun L, Tan L, et al. (2013) Genetic variation in Clusterin gene and Alzheimer's disease risk in Han Chinese. Neurobiol Aging 34: 1921.e1917-1923.
13. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, et al. (2010) Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67: 739-748.
14. Craft S (2012) Alzheimer disease: Insulin resistance and AD-extending the translational path. Nat Rev Neurol 8: 360-362.
15. Profenno LA, Porsteinsson AP, Faraone SV (2010) Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry 67: 505-512.
16. International Obesity Task Force (IOTF) (2000) The Asia-Pacific perspective: Redefining Obesity and its Treatment. WHO West Pacific Region, Sydney, Australia.
17. Fukushima M, Taniguchi A, Sakai M, Doi K, Nagasaka S, et al. (1999) Homeostasis model assessment as a clinical index of insulin resistance. Comparison with the minimal model analysis. Diabetes Care 22: 1911-1912. (Pubitemid 29521888)
18. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752. (Pubitemid 41532612)
19. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, et al. (2009) Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640-1645.
20. Albert MA, Glynn RJ, Ridker PM (2003) Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 108: 161-165. (Pubitemid 36871297)
21. Meisinger C, Koenig W, Baumert J, Doring A (2008) Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MONICA/KORA cohort study. Arterioscler Thromb Vasc Biol 28: 1186-1192.
22. Fernandez-Real JM, Ricart-Engel W, Arroyo E, Balanca R, Casamitjana-Abella R, et al. (1998) Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 21: 62-68. (Pubitemid 28030387)
23. Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, et al. (2007) Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 92: 2590-2597. (Pubitemid 47037362)
24. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444: 860-867.
25. Tamakoshi K, Yatsuya H, Kondo T, Hori Y, Ishikawa M, et al. (2003) The metabolic syndrome is associated with elevated circulating C-reactive protein in healthy reference range, a systemic low-grade inflammatory state. Int J Obes Relat Metab Disord 27: 443-449. (Pubitemid 36520842)
26. Bhamra MS, Ashton NJ (2012) Finding a pathological diagnosis for Alzheimer's disease: are inflammatory molecules the answer? Electrophoresis 33: 3598-3607.
27. Kujiraoka T, Hattori H, Miwa Y, Ishihara M, Ueno T, et al. (2006) Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. J Atheroscler Thromb 13: 314-322.
28. Arnold T, Brandlhofer S, Vrtikapa K, Stangl H, Hermann M, et al. (2011) Effect of obesity on plasma clusterin, [corrected] a proposed modulator of leptin action. Pediatr Res 69: 237-242.
29. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752. (Pubitemid 41532612)
30. Navab M, Hama-Levy S, Van Lenten BJ, Fonarow GC, Cardinez CJ, et al. (1997) Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest 99: 2005-2019. (Pubitemid 27175949)
31. Trougakos IP, Poulakou M, Stathatos M, Chalikia A, Melidonis A, et al. (2002) Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Exp Gerontol 37: 1175-1187. (Pubitemid 35418275)
32. Burkey BF, Stuart WD, Harmony JA (1992) Hepatic apolipoprotein J is secreted as a lipoprotein. J Lipid Res 33: 1517-1526.
33. Hardardottir I, Kunitake ST, Moser AH, Doerrler WT, Rapp JH, et al. (1994) Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Invest 94: 1304-1309. (Pubitemid 24286476)
34. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, et al. (2003) Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23: 434-439. (Pubitemid 36337219)
35. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC, et al. (1994) Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33: 832-839. (Pubitemid 24064123)
36. Ishikawa Y, Ishii T, Akasaka Y, Masuda T, Strong JP, et al. (2001) Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study. Atherosclerosis 158: 215-225. (Pubitemid 32735487)
37. Kim HJ, Yoo EK, Kim JY, Choi YK, Lee HJ, et al. (2009) Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc Biol 29: 1558-1564.
38. Shirasawa T, Miyata M, Eto H, Hamada N, Akasaki Y, et al. (2009) Deficiency of clusterin inhibits neointimal hyperplasia after vascular injury. J Atheroscler Thromb 16: 772-781.